Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PTCT Stock Summary
Top 10 Correlated ETFs
PTCT
In the News
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.
PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $0.29. This compares to loss of $2.35 per share a year ago.
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: TD Cowen 44th Annual Health Care Conference Monday, March 4, at 1:30 p.m.
PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing
The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the company said on Thursday.
PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2023 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O'Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Eric Joseph - J.P. Morgan Kristen Kluska - Cantor Fitzgerald Samantha Corwin - William Blair David Lebowitz - Citi Brian Abrahams - RBC Capital Markets Colin Bristow - UBS Jeff Hung - Morgan Stanley Alexander Xenakis - Truist Securities Joseph Schwartz - Leerink Partners Gena Wang - Barclays Paul Choi - Goldman Sachs Tazeen Ahmad - Bank of America Operator Thank you for standing by and welcome to the PTC Therapeutics Third Quarter 2023 Financial Results Conference Call.
Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?
PTC Therapeutics (NASDAQ: PTCT ) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with its earnings per share of -$1.76.
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $1.53 per share a year ago.
PTCT Financial details
PTCT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.22 | 5.77 | 7.64 | 9.74 | 12.53 | |
Net income per share | -4.27 | -6.64 | -7.43 | -7.79 | -8.37 | |
Operating cash flow per share | -1.68 | -2.94 | -3.57 | -4.97 | -2.12 | |
Free cash flow per share | -2.45 | -3.79 | -4.78 | -7.1 | -3.73 | |
Cash per share | 18.43 | 16.71 | 19.26 | 7.55 | 11.72 | |
Book value per share | 10.1 | 7.3 | 0.02 | -4.84 | -10.94 | |
Tangible book value per share | -3.37 | -4.78 | -11.43 | -15.83 | -17.11 | |
Share holders equity per share | 10.1 | 7.3 | 0.02 | -4.84 | -10.94 | |
Interest debt per share | 5.12 | 7.22 | 9.61 | 11.08 | 5.74 | |
Market cap | 2.83B | 4.03B | 2.81B | 2.74B | 2.06B | |
Enterprise value | 2.45B | 4.24B | 2.46B | 3.03B | 1.88B | |
P/E ratio | -11.24 | -9.2 | -5.36 | -4.9 | -3.29 | |
Price to sales ratio | 9.21 | 10.58 | 5.21 | 3.92 | 2.2 | |
POCF ratio | -28.66 | -20.76 | -11.17 | -7.68 | -13.02 | |
PFCF ratio | -19.62 | -16.12 | -8.34 | -5.38 | -7.39 | |
P/B Ratio | 4.76 | 8.36 | 1.95K | -7.89 | -2.52 | |
PTB ratio | 4.76 | 8.36 | 1.95K | -7.89 | -2.52 | |
EV to sales | 8 | 11.14 | 4.58 | 4.34 | 2.01 | |
Enterprise value over EBITDA | -21.02 | -18.62 | -6.52 | -8.13 | -16.7 | |
EV to operating cash flow | -24.88 | -21.85 | -9.81 | -8.5 | -11.89 | |
EV to free cash flow | -17.04 | -16.96 | -7.32 | -5.95 | -6.75 | |
Earnings yield | -0.09 | -0.11 | -0.19 | -0.2 | -0.3 | |
Free cash flow yield | -0.05 | -0.06 | -0.12 | -0.19 | -0.14 | |
Debt to equity | 0.53 | 0.87 | 411.16 | -2.03 | -0.37 | |
Debt to assets | 0.19 | 0.19 | 0.31 | 0.41 | 0.16 | |
Net debt to EBITDA | 3.19 | -0.93 | 0.9 | -0.79 | 1.59 | |
Current ratio | 3.3 | 4.44 | 1.52 | 1.71 | 2.02 | |
Interest coverage | 15.43 | -7.06 | -4.36 | -4.84 | -2.7 | |
Income quality | 0.39 | 0.44 | 0.48 | 0.64 | 0.25 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.84 | 1.25 | 1 | 0.93 | 0.71 | |
Intangibles to total assets | 0.49 | 0.36 | 0.42 | 0.46 | 0.24 | |
Capex to operating cash flow | 0.46 | 0.29 | 0.34 | 0.43 | 0.76 | |
Capex to revenue | -0.15 | -0.15 | -0.16 | -0.22 | -0.13 | |
Capex to depreciation | -1.41 | -0.66 | -1.33 | -1.18 | -0.51 | |
Stock based compensation to revenue | 0.14 | 0.18 | 0.19 | 0.16 | 0.14 | |
Graham number | 31.16 | 33.01 | 1.85 | 29.13 | 45.39 | |
ROIC | -0.22 | -0.43 | -0.54 | -0.86 | 0.78 | |
Return on tangible assets | -0.3 | -0.31 | -0.46 | -0.61 | -0.43 | |
Graham Net | 1.82 | -8.49 | -6.94 | -19.29 | -22.84 | |
Working capital | 543.43M | 954.41M | 264.03M | 287.55M | 615.53M | |
Tangible asset value | -198.51M | -315.69M | -805.74M | -1.14B | -1.28B | |
Net current asset value | -250.17M | -494.55M | -1.16B | -1.36B | -1.5B | |
Invested capital | 0.53 | 0.87 | 411.16 | -2.03 | -0.37 | |
Average receivables | 61.72M | 62.73M | 90.19M | 133.03M | 158.32M | |
Average payables | 8.16M | 14.49M | 20.85M | 25.15M | 16.66M | |
Average inventory | 17.7M | 18.99M | 17.28M | 18.83M | 26.19M | |
Days sales outstanding | 66.03 | 67.03 | 74.85 | 81.28 | 62.67 | |
Days payables outstanding | 310.53 | 359.66 | 260.05 | 222.77 | 7.66 | |
Days of inventory on hand | 580.06 | 360.28 | 179.02 | 178.16 | 38.74 | |
Receivables turnover | 5.53 | 5.45 | 4.88 | 4.49 | 5.82 | |
Payables turnover | 1.18 | 1.01 | 1.4 | 1.64 | 47.66 | |
Inventory turnover | 0.63 | 1.01 | 2.04 | 2.05 | 9.42 | |
ROE | -0.42 | -0.91 | -364.33 | 1.61 | 0.77 | |
Capex per share | -0.77 | -0.85 | -1.21 | -2.13 | -1.61 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.31 | 2.99 | 2.86 | 2.61 | 4.07 | |
Net income per share | -2.36 | -1.88 | -2.66 | -1.76 | -2.06 | |
Operating cash flow per share | -2.29 | -0.4 | -0.19 | -0.19 | -1.33 | |
Free cash flow per share | -2.66 | -0.99 | -0.45 | -0.58 | -1.71 | |
Cash per share | 7.47 | 3.88 | 4.52 | 3.91 | 11.61 | |
Book value per share | -4.79 | -6.21 | -7.75 | -8.9 | -10.84 | |
Tangible book value per share | -15.66 | -16.63 | -14.9 | -15.61 | -16.96 | |
Share holders equity per share | -4.79 | -6.21 | -7.75 | -8.9 | -10.84 | |
Interest debt per share | 10.04 | 9.88 | 9.8 | 8.97 | 4.56 | |
Market cap | 2.77B | 3.57B | 3.04B | 1.69B | 2.08B | |
Enterprise value | 3.06B | 4.11B | 3.53B | 2.23B | 1.9B | |
P/E ratio | -4.05 | -6.43 | -3.82 | -3.18 | -3.34 | |
Price to sales ratio | 16.53 | 16.21 | 14.22 | 8.59 | 6.78 | |
POCF ratio | -16.68 | -121.1 | -215.25 | -116.35 | -20.75 | |
PFCF ratio | -14.34 | -48.82 | -90.99 | -38.63 | -16.16 | |
P/B Ratio | -7.97 | -7.81 | -5.25 | -2.52 | -2.54 | |
PTB ratio | -7.97 | -7.81 | -5.25 | -2.52 | -2.54 | |
EV to sales | 18.28 | 18.63 | 16.53 | 11.34 | 6.19 | |
Enterprise value over EBITDA | -34.1 | -62.35 | -51.84 | -18.86 | 22.69 | |
EV to operating cash flow | -18.44 | -139.2 | -250.25 | -153.48 | -18.97 | |
EV to free cash flow | -15.86 | -56.11 | -105.78 | -50.96 | -14.77 | |
Earnings yield | -0.06 | -0.04 | -0.07 | -0.08 | -0.07 | |
Free cash flow yield | -0.07 | -0.02 | -0.01 | -0.03 | -0.06 | |
Debt to equity | -2.03 | -1.53 | -1.21 | -1.05 | -0.37 | |
Debt to assets | 0.41 | 0.44 | 0.53 | 0.56 | 0.16 | |
Net debt to EBITDA | -3.26 | -8.11 | -7.25 | -4.56 | -2.14 | |
Current ratio | 1.71 | 1.39 | 1.24 | 1.1 | 2.02 | |
Interest coverage | -6.56 | -4.22 | -7.12 | 4.2 | 0.07 | |
Income quality | 0.97 | 0.21 | 0.07 | 0.11 | 0.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0.41 | 0.26 | |
Research and developement to revenue | 1.13 | 0.89 | 0.87 | 0.84 | 0.4 | |
Intangibles to total assets | 0.46 | 0.48 | 0.4 | 0.4 | 0.24 | |
Capex to operating cash flow | 0.16 | 1.48 | 1.37 | 2.01 | 0.28 | |
Capex to revenue | -0.16 | -0.2 | -0.09 | -0.15 | -0.09 | |
Capex to depreciation | -0.69 | -1.02 | -0.38 | -0.47 | -0.35 | |
Stock based compensation to revenue | 0.16 | 0.13 | 0.14 | 0.29 | 0.05 | |
Graham number | 15.93 | 16.22 | 21.54 | 18.79 | 22.43 | |
ROIC | -0.3 | -0.32 | -0.69 | -0.57 | -0.01 | |
Return on tangible assets | -0.19 | -0.17 | -0.25 | -0.18 | -0.11 | |
Graham Net | -19.08 | -21.91 | -19.14 | -19.82 | -22.63 | |
Working capital | 287.55M | 171.76M | 113.35M | 48.24M | 615.53M | |
Tangible asset value | -1.14B | -1.23B | -1.11B | -1.18B | -1.28B | |
Net current asset value | -1.36B | -1.45B | -1.33B | -1.39B | -1.5B | |
Invested capital | -2.03 | -1.53 | -1.21 | -1.05 | -0.37 | |
Average receivables | 140.04M | 178.74M | 189.69M | 171.61M | 163.37M | |
Average payables | 24.07M | 26.79M | 26.03M | 22.45M | 12.6M | |
Average inventory | 18.31M | 24.23M | 29.33M | 33.89M | 33.16M | |
Days sales outstanding | 83.66 | 82.44 | 74.72 | 75.87 | 47.2 | |
Days payables outstanding | 225.29 | 167.42 | 181.97 | 181.57 | 5.12 | |
Days of inventory on hand | 180.18 | 169.57 | 226.35 | 338.95 | 25.89 | |
Receivables turnover | 1.08 | 1.09 | 1.2 | 1.19 | 1.91 | |
Payables turnover | 0.4 | 0.54 | 0.49 | 0.5 | 17.58 | |
Inventory turnover | 0.5 | 0.53 | 0.4 | 0.27 | 3.48 | |
ROE | 0.49 | 0.3 | 0.34 | 0.2 | 0.19 | |
Capex per share | -0.37 | -0.59 | -0.26 | -0.39 | -0.38 |
PTCT Frequently Asked Questions
What is PTC Therapeutics, Inc. stock symbol ?
PTC Therapeutics, Inc. is a US stock , located in South plainfield of Nj and trading under the symbol PTCT
Is PTC Therapeutics, Inc. buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $47.25. The lowest prediction is $35 and the highest is $63
What is PTCT stock prediction ?
What is PTC Therapeutics, Inc. stock quote today ?
PTC Therapeutics, Inc. stock price is $29.09 today.
Is PTC Therapeutics, Inc. stock public?
Yes, PTC Therapeutics, Inc. is a publicly traded company.